Alloptic Granted Patent for Point-To-Multipoint Passive Optical Network That Utilizes Variable-Length Packets

Alloptic, a global leader in the development of RF over glass (RFoG) and passive optical networking (PON) solutions for CATV, telecom, and private network operators worldwide, today announced that it has been granted a patent by the Japan Patent Office for "Point-To-Multipoint Passive Optical Network That Utilizes Variable-Length Packets" (No. 2002-546329284479). Fiber-to-the-Home and Fiber-to-the-Business PON systems carry variable-length IP or Ethernet packets, which often must be fragmented and encapsulated into fixed-length frames for transmission. This patent applies to the way in which that critical function occurs in popular PON technologies that are deployed not only in Japan, but also around the globe.

Japan is the fourth country to affirm Alloptic’s intellectual property rights for this technology, adding to the list of similar patents held in the United States (U.S. Pat. 7,031,343), Taiwan (#90128223), and China (#ZL01821736.2).

“We are pleased to receive this patent,” said Ric Johnsen, Alloptic President and CEO. “The broad geographic protection we received for our intellectual property is a testament to the innovation and contributions Alloptic makes to the communications industry.”

Alloptic was the first company to develop an Ethernet-based PON product, and it continues to introduce new technology to the communications community. Alloptic systems are in use around the world and offer years of field-hardened operational experience. Alloptic solutions leverage industry-standard protocols and architectures with cutting-edge technology to deliver gigabits of bandwidth to residential and business users. Alloptic provides a full suite of emerging and legacy services for the complete range of voice, data, and video applications.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.